Regeneron Pharmaceuticals Top Holdings: A Deep Dive into NTLA

Regeneron Pharmaceuticals, Inc. (regeneron-pharmaceuticals-inc) held a substantial portfolio valued at $62,654,675 as of June 30, 2026. This analysis focuses on the investor's top holdings based on their weight within this portfolio.

The most significant position in Regeneron Pharmaceuticals' portfolio was Intellia Therapeutics, Inc. (NTLA). This stock accounted for a considerable 35.35% allocation of the total $62.7 million portfolio value.

Regarding Intellia Therapeutics, Regeneron Pharmaceuticals maintained an unwavering position throughout the reporting period, as evidenced by zero changes in shares held and no fluctuation in its percentage allocation within the portfolio (Intellia Therapeutics profile). This indicates a strong conviction on the part of Regeneron Pharmaceuticals towards this particular stock.

Examining Intellia Therapeutics (NTLA), it operates in the highly competitive Healthcare sector, specifically within the realm of biotechnology. The company focuses on developing CRISPR-Cas9 genome editing therapeutics for serious diseases. Regeneron Pharmaceuticals' investment underscores its interest in this cutting-edge field.

While Regeneron Pharmaceuticals' portfolio contained only one holding, it was fully allocated to the Healthcare sector. This single-stock allocation of 35.35% represents a high concentration risk for the investor.

It's important to note that Regeneron Pharmaceuticals did not alter its position in Intellia Therapeutics during this period, with no change in shares or percentage allocation reported. This lack of movement suggests stability but also points to a portfolio heavily reliant on the performance of just one stock.

The data shows that Regeneron Pharmaceuticals' portfolio held only one position as of June 30, 2026: Intellia Therapeutics (NTLA). This singular holding accounted for the entire $62.7 million value and sector allocation.